



DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD

Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study

The Harvard community has made this article openly available. [Please share](#) how this access benefits you. Your story matters.

Citation	Darling, C. E., J. A. Sala Mercado, W. Quiroga-Castro, G. F. Tecco, F. R. Zelaya, E. C. Conci, J. P. Sala, et al. 2014. "Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study." <i>BMJ Open</i> 4 (1): e003883. doi:10.1136/bmjopen-2013-003883. http://dx.doi.org/10.1136/bmjopen-2013-003883 .
Published Version	doi:10.1136/bmjopen-2013-003883
Accessed	February 19, 2015 3:16:33 PM EST
Citable Link	http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879652
Terms of Use	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

(Article begins on next page)

BMJ Open Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study

Chad E Darling,¹ Javier A Sala Mercado,^{2,3,4} Walter Quiroga-Castro,⁴ Gabriel F Tecco,⁴ Felix R Zelaya,⁴ Eduardo C Conci,⁴ Jose P Sala,⁴ Craig S Smith,⁵ Alan D Michelson,⁶ Peter Whittaker,^{1,2,7} Robert D Welch,^{2,7} Karin Przyklenk^{1,2,3,7}

To cite: Darling CE, Sala Mercado JA, Quiroga-Castro W, *et al.* Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study. *BMJ Open* 2014;**4**:e003883. doi:10.1136/bmjopen-2013-003883

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2013-003883>).

Received 23 August 2013
Revised 26 November 2013
Accepted 19 December 2013



CrossMark

For numbered affiliations see end of article.

Correspondence to

Professor Karin Przyklenk;
kprzykle@med.wayne.edu

ABSTRACT

Objective: Accurate, efficient and cost-effective disposition of patients presenting to emergency departments (EDs) with symptoms suggestive of acute coronary syndromes (ACS) is a growing priority. Platelet activation is an early feature in the pathogenesis of ACS; thus, we sought to obtain an insight into whether point-of-care testing of platelet function: (1) may assist in the rule-out of ACS; (2) may provide additional predictive value in identifying patients with non-cardiac symptoms versus ACS-positive patients and (3) is logistically feasible in the ED.

Design: Prospective cohort feasibility study.

Setting: Two urban tertiary care sites, one located in the USA and the second in Argentina.

Participants: 509 adult patients presenting with symptoms of ACS.

Main outcome measures: Platelet reactivity was quantified using the Platelet Function Analyzer-100, with closure time (seconds required for blood, aspirated under high shear, to occlude a 150 µm aperture) serving as the primary endpoint. Closure times were categorised as 'normal' or 'prolonged', defined objectively as the 90th centile of the distribution for all participants enrolled in the study. Diagnosis of ACS was made using the standard criteria. The use of antiplatelet agents was not an exclusion criterion.

Results: Closure times for the study population ranged from 47 to 300 s, with a 90th centile value of 138 s. The proportion of patients with closure times ≥ 138 s was significantly higher in patients with non-cardiac symptoms (41/330; 12.4%) versus the ACS-positive cohort (2/105 (1.9%); $p=0.0006$). The specificity of 'prolonged' closure times (≥ 138 s) for a diagnosis of non-cardiac symptoms was 98.1%, with a positive predictive value of 95.4%. Multivariate analysis revealed that the closure time provided incremental, independent predictive value in the rule-out of ACS.

Conclusions: Point-of-care assessment of platelet reactivity is feasible in the ED and may facilitate the rapid rule-out of ACS in patients with prolonged closure times.

Strengths and limitations of this study

- The study suggests that a technically straightforward and cost-effective test, with minimal patient risk, may serve as a useful adjunct to the current, standard emergency department practices for the rule-out of acute coronary syndromes. Importantly, the results are generalisable: the observation of a higher incidence of prolonged closure times in patients with non-cardiac symptoms was seen in participants from two distinct healthcare systems and populations.
- Platelet Function Analyzer-100 testing will only contribute to the identification of a subset of patients with non-cardiac symptoms, with the size of the subset and the potential value of the test dependent on the threshold used to define the 'prolonged' closure times.
- Limitations of this pilot study include the enrolment of patients via convenience sampling, the fact that patient outcomes were not monitored beyond hospital discharge and that a risk/benefit analysis was not included in the study design.

Accurate, efficient and cost-effective diagnosis of patients presenting to emergency departments (EDs) with symptoms suggestive of acute coronary syndromes (ACS)—and, in particular, the exclusion and early discharge of patients with non-cardiac chest pain—is a growing priority.^{1–2} In an effort to meet this challenge, interest has focused on the identification of new approaches to augment the standard ED procedures and facilitate the timely triage of patients with suspected ACS. For example, there is recent evidence that coronary CT angiography (CCTA) combined with routine clinical assessment may provide added prognostic value in the management of chest pain patients in the ED.^{3–8} Use of

CCTA in low-to-intermediate risk patients is reportedly safe and reduces ED costs and hospital length of stay.^{3–5} However, these benefits are accompanied by exposure to radiation and associated with increases in diagnostic testing and subsequent invasive procedures.^{5–8}

Assessment of platelet activation, an early feature in the pathogenesis of ACS,^{9–14} has also been investigated as a possible benign strategy to expedite the diagnosis of ACS.^{15–16} Application of flow cytometry, the ‘gold standard’ for the quantitation of molecular indices of platelet activation, is, however, impractical for routine use under emergent conditions.^{11–12–17–18} More importantly, classic molecular indices of platelet activation have not provided added benefit in the risk stratification of undifferentiated chest pain patients.^{15–16}

We hypothesised that rapid assessment of platelet reactivity using a technically straightforward point-of-care device—specifically, the Platelet Function Analyzer (PFA)-100 (Siemens)—may represent a more feasible strategy to assist in the timely rule-out of ACS in the ED. Rather than quantifying molecular markers of platelet activation-aggregation, the output of the PFA-100 is the ‘closure time’: that is, the time required for whole blood, aspirated under high shear, to occlude a small, 150 µm aperture in a membrane coated with standard platelet agonists (collagen-ADP or collagen-epinephrine). Although the PFA-100 is typically utilised to investigate the responsiveness of patients to aspirin and other antiplatelet therapies and aid in the detection of platelet dysfunction,^{11–12–18–22} there is evidence to suggest that shortened closure times may be a marker of the acuity of coronary disease.¹⁰ Accordingly, our primary aims in this pilot study were to determine whether point-of-care testing of platelet function: (1) may assist in the rule-out of ACS; (2) may yield additional predictive value in identifying patients with non-cardiac symptoms versus ACS-positive patients and (3) is logistically feasible in an emergent setting. In addition, as a secondary analysis, we investigated whether the closure time may be of value in discriminating between ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI)/unstable angina (UA).

METHODS

We conducted a prospective cohort feasibility study of patients presenting with potential ACS at two urban tertiary care sites: the ED at the University of Massachusetts (UMASS)-Memorial Medical Center, University Campus, Worcester, Massachusetts, USA, and the Cardiology Department, Instituto Modelo de Cardiologia Privado SRL, Cordoba, Argentina. The enrolment period was from January 2007 to December 2010. At each site, patients were entered on a convenience basis: that is, enrolments were not consecutive but, rather, coincided with the work schedules of the study investigators.

Patient population

Patients ≥18 years of age with a potential diagnosis of ACS (at the discretion of the treating physician and reflected

by orders for an ECG and cardiac biomarkers) were considered for enrolment in the study. The prospective exclusion criteria were pregnancy, renal insufficiency (defined as serum creatine levels ≥1.5 mg/dL), anaemia (haematocrit <30%), platelet count <100 000/µL, major bleeding, any gastrointestinal bleeding, trauma or the inability to provide informed consent for any reason. The use of antiplatelet agents was not an exclusion criterion.

Study enrolment and protocol

As soon as possible after evaluation by ED staff, potential participants were approached for enrolment into the study. If the patient was too ill or otherwise unable to provide written consent, then proxy consent was attempted. If consent was obtained by proxy and the patient later became cognisant, they were given the option to continue or withdraw their participation in the study. If consent was withdrawn, all collected data were discarded.

Blood used in the PFA-100 was drawn within <1 h after presentation, at the same time as cardiac biomarker testing, and the closure time was measured within 3 h of collection. All samples were obtained via peripheral venipuncture and drawn into tubes containing 3.2% sodium citrate. Immediately before analysis, each sample was gently inverted; a 900 µL aliquot of whole blood was then applied to a collagen-ADP test cartridge and the closure time was quantified. Maximum test duration for the PFA-100 is 5 min; if the aperture is not occluded within this period, a closure time of ‘>300 s’ is displayed.

On enrolment, patients were questioned regarding a history of bleeding or platelet function disorders and ingestion of known antiplatelet agents within the past 7 days (aspirin, clopidogrel, non-steroidal anti-inflammatory agents). In addition, the medical record was reviewed and the standard cardiac risk factors (diabetes, hypertension, hypercholesterolaemia, smoking, family history of heart disease) were recorded and used in the calculation of thrombolysis in myocardial infarction (TIMI) risk score.²³

Patient diagnosis

The final diagnosis (non-cardiac symptoms vs ACS-positive) was established via a standardised chart review. All reviews were conducted by physicians in a blinded manner, without knowledge of the closure time data. For participants enrolled at the Instituto Modelo de Cardiologia Privado, patients were seen by a cardiologist at the time of hospital presentation, and all reviews were performed by a team of cardiologists (WQ-C, GFT, FRZ, ECC and JPS). At UMASS, each patient was first seen by an Emergency Medicine physician at the time of hospital presentation, and each chart was reviewed by an ED physician (CED). For patients with a definitive diagnosis of non-cardiac symptoms (ie, patients with no ischaemic ECG changes, no positive markers or provocative cardiovascular test results, and no history of a diagnosis of ACS of any type in the chart), no additional

review was performed. However, for patients who: (1) had positive cardiac biomarkers during admission; (2) underwent cardiac catheterisation; (3) had a positive provocative cardiovascular test (eg, exercise stress test) or (4) had ischaemic ECG changes, the chart was reviewed by an ED physician and a cardiologist. In any case in which the diagnosis was uncertain, the decision was adjudicated by a cardiologist (CSS).

Patients considered to be ACS positive were categorised into one of the two groups, STEMI or NSTEMI/UA, in accordance with the standard guidelines.^{24–26} Patients who did not meet these criteria were classified as having a diagnosis of non-cardiac chest pain/symptoms.

Statistical analysis

Our target sample size in this exploratory study was empiric. We reasoned that, as an approximate order of magnitude, ~100 patients would be required in the ACS-positive group in order to have the likelihood of discerning a potential difference in the closure times between patients with non-cardiac symptoms and the ACS-positive cohort. Assuming that 75% of patients enrolled in the study would have a diagnosis of non-cardiac chest pain (and thus 25% would be ACS positive), a total of approximately 400 patients would be required. To account for exclusions, target enrolment was set at ~500 participants.

Univariate comparisons

Our primary analyses focused on the comparison of patients in the two main outcome groups: non-cardiac symptoms versus ACS positive. All categorical data were compared using the Fisher's exact test and are reported as percentages. For continuous data, the D'Agostino and Pearson test was applied to determine normality and the appropriate parametric (t test) or non-parametric alternative (Mann-Whitney) tests were utilised. Secondary analysis (comparison of closure times among non-cardiac chest pain, STEMI and NSTEMI/UA groups) was conducted using the Kruskal-Wallis test. Results are reported as mean±SD or medians with associated 10th and 90th centile ranges.

Sensitivity, specificity and multivariate analysis

We made the prospective and arbitrary decision to categorise the closure time into 'normal' and "prolonged" values based on the 90th centile of the distribution for all patients enrolled in the study. Utilising the normal and prolonged values of closure time, the sensitivity, specificity, negative and positive predictive values and likelihood ratio for identifying patients with *non-cardiac symptoms* were determined. Two reasons contributed to our choice of non-cardiac chest pain (rather than ACS positive) as the main outcome of interest: (1) this approach is consistent with current guidelines for the improvement of diagnostic accuracy^{1 8} and (2) we reasoned that prolonged closure times may be associated with the absence of ACS, whereas shorter closure times

may be manifest in either group of patients. Sensitivity, specificity, predictive values and the likelihood ratio are reported with associated 95% CIs.

To determine whether the PFA closure time provides an additional predictive value to the standard clinical diagnostic information, a logistic regression was developed to assess its independent association with the main outcome of non-cardiac symptoms. Independent predictor variables considered to be mandatory in the model were the closure time (utilising continuous rather than the categorised values; the main predictor of interest) and the TIMI risk score (representing standard clinical information to predict ACS outcomes). To account for potential differences between UMASS and Cordoba, the study site was also added to the regression model. Other non-mandatory variables considered for inclusion were sex, a medical history of diabetes, hypertension, hypercholesterolaemia, smoking and clopidogrel use. As age and aspirin use are individually incorporated in the TIMI risk score, these variables were not considered for separate inclusion in the model. Non-mandatory variables were left in the model only if they yielded an increase in predictive value as determined by receiver operating characteristic (ROC) analysis or were of additional importance based on the 2 log-likelihood ratio test.

The reported estimate and adjusted OR for closure time were calculated for an increase in platelet closure time of 10 s (rather than 1 s), a choice based on the premise that a 1 s increase would be of limited clinical usefulness. The final model was evaluated by c-statistic (area under the ROC curve) and the Hosmer and Lemeshow fit test. As a sensitivity test, the results were calculated using the general estimating equation (PROC GENMOD) with study site evaluated as a subject factor (cluster) rather than a term in the model. The Net Reclassification Index (NRI) and Integrated Discrimination Improvement (IDI) statistic were not included in the analyses, given the scepticism and criticisms that have been raised concerning their value in predicting the potential, incremental prognostic impact of novel biomarkers.^{27 28}


Analyses were performed using GraphPad Prism V.5.04 (San Diego, California, USA) and SAS V.9.3 (Carey, North Carolina, USA).

RESULTS

Enrolment and exclusions

A combined total of 509 patients were enrolled at the two study sites (figure 1). Sixty-one participants were excluded because the closure time data were not available. The reasons included technical errors (n=14), closure times >300 s (possibly due to mild thrombocytopenia, anaemia or inadequate mixing of the blood sample prior to testing; n=36) and failure to measure the closure time despite obtaining consent (n=11). An additional five participants were removed from analysis because exclusion criteria were

Figure 1 Inclusion flow chart.



identified after consent was obtained (n=4), or consent was revoked after the blood sample was collected (n=1). For the remaining 443 patients in whom the closure time was quantified, 8 were diagnosed with thrombotic events that were non-cardiac in origin and thus were excluded from further analysis. Accordingly, results are reported for 435 participants (324 enrolled at UMASS and 111 enrolled in Cordoba): 105 were diagnosed with ACS and 330 had non-cardiac symptoms.

Demographics


As expected,²⁹ the ACS-positive group had higher TIMI scores, was older, and had a higher proportion of male participants versus patients with non-cardiac symptoms (table 1). In addition, the incidence of hypercholesterolaemia and the use of clopidogrel were significantly higher in the ACS group. There were, however, no differences in the use of aspirin, incidence of hypertension or diabetes, proportion of smokers or a reported family history of heart disease between the two groups.

Table 1 Demographics: all patients

	Non-cardiac symptoms (total n=330)	ACS positive (total n=105)	p Value
Age (years): mean±SD	57±14 (n=328)	61±13 (n=104)	0.034
Male	65% (n=330)	80% (n=105)	0.004
TIMI score: mean±SD	1.9±1.4 (n=320)	3.1±1.4 (n=104)	<0.0001
Aspirin	71% (n=321)	64% (n=104)	0.222 (ns)
Clopidogrel	11% (n=325)	20% (n=104)	0.031
Smoker	29% (n=322)	28% (n=105)	0.901 (ns)
Hypertension	57% (n=322)	62% (n=105)	0.425 (ns)
Hypercholesterolaemia	57% (n=322)	69% (n=105)	0.030
Diabetes	24% (n=322)	27% (n=105)	0.601 (ns)
Family history	40% (n=319)	41% (n=105)	0.909 (ns)

ACS, acute coronary syndromes; TIMI, thrombolysis in myocardial infarction.

Figure 2 Platelet Function Analyzer-100 closure time (s). (A) Median values with 10th, 25th, 75th and 90th centiles: acute coronary syndromes (ACS)-positive patients and patients with non-cardiac symptoms. (B) Individual data points for all participants: ACS-positive patients and patients with non-cardiac symptoms. Lines denote the 80th, 90th and 95th centiles of closure times for all patients enrolled in the study. (C) Individual data points for all participants: ST-elevation myocardial infarction, non-ST-elevation myocardial infarction/unstable angina cohorts and patients with non-cardiac symptoms. Lines denote the 80th, 90th and 95th centiles of closure times for all patients enrolled in the study.



Closure time

There was a modest but significant difference in the median closure times in patients with non-cardiac symptoms versus the ACS-positive group: 91 vs 87 s, respectively ($p=0.0061$; [figure 2A](#)). When the ACS-positive group was divided into STEMI and combined NSTEMI/UA cohorts, the modest differences in the closure time in the secondary three-group analysis remained significant ($p=0.0001$; [figure 2C](#)).

Of potentially greater importance, patients with non-cardiac symptoms versus ACS-positive patients were distinguished by differences in the proportion of the prolonged closure times. We found that 41/330 (12.4%) of patients with non-cardiac symptoms had closure times ≥ 138 s (ie, the 90th centile of the distribution for all

patients enrolled in the study) while, in contrast, 2/105 (1.9%) of patients in the ACS-positive group had closure times \geq this value ($p=0.0006$; [figure 2B](#) and [table 2](#)). The specificity and sensitivity of 'prolonged' closure times (≥ 138 s) for a diagnosis of non-cardiac symptoms were 98.1% and 12.4%, respectively, with a positive predictive value of 95.4%, a negative predictive value of 26.3% and a likelihood ratio of 6.52 ([table 3](#)).

Site differences: UMASS versus Cordoba

Patients at both sites displayed the expected differences in TIMI score, age and sex between non-cardiac chest pain and ACS-positive groups (data not shown). However, the participants enrolled in Cordoba were significantly younger, with a higher proportion of males

Table 2 Incidence of prolonged closure time (≥ 138 s, defined as the 90th centile of the distribution of the study population)

	Non-cardiac symptoms	ACS positive	Total
Prolonged closure time			
Yes	41	2	43
No	289	103	392
Total	330	105	435

ACS, acute coronary syndromes.

and smokers but lower proportion of patients with diabetes, when compared with UMASS (table 4). In addition, and as expected,^{30 31} aspirin use was significantly lower among the cohort in Cordoba versus the UMASS population (40% vs 80%, $p < 0.0001$, table 4). Despite these demographic differences, a higher incidence of prolonged closure times in patients with non-cardiac symptoms was observed at both sites: that is, the proportion of participants with closure times ≥ 138 s was 13% vs 10% in patients with non-cardiac chest pain and 1.9% vs 2% in ACS-positive patients at UMASS versus Cordoba, respectively.

Closure time as an independent predictor of diagnosis

Logistic regression analysis was first performed with mandatory variables (closure time, TIMI risk score) and non-mandatory variables (study site, sex, diabetes, hypertension, hypercholesterolaemia, smoking, clopidogrel use) included in the regression model (data not shown). ROC analysis revealed that, among the non-mandatory variables, only study site (UMASS vs Cordoba) contributed to an increase to the predictive value of the model for a diagnosis of non-cardiac symptoms. Comparison of ROC curves obtained by including the closure time, TIMI score and site in the model versus TIMI score and site alone showed a significant, incremental increase in area under the curve with the addition of closure time (0.818 vs 0.795; $p = 0.009$; figure 3). Accordingly, the final multivariate logistic regression model incorporated these three variables (table 5).

For every 10 s increase in the closure time, the adjusted odds of a diagnosis of non-cardiac symptoms

Table 3 Sensitivity, specificity, positive and negative predictive values and likelihood ratio of prolonged closure time for a diagnosis of non-cardiac symptoms

	95% CI	
Sensitivity (%)	12.4	9.1 to 16.5
Specificity (%)	98.1	93.3 to 99.8
Positive predictive value (%)	95.4	84.2 to 99.4
Negative predictive value (%)	26.3	22.0 to 30.9
Likelihood ratio	6.52	1.61 to 26.51

was 1.17 (95% CI 1.06 to 1.29; table 5). That is, when controlling for TIMI risk score and study site: for every 10 s increase, the prolonged closure time was associated with a 17% increase in the patient having non-cardiac chest pain. These results demonstrate that, *irrespective of TIMI score and site*, the closure time was associated with the diagnosis of non-cardiac symptoms, with *closure time providing additional, incremental predictive value beyond that obtained by TIMI score*. The model demonstrated good predictive characteristics ($c = 0.82$) and model fit ($\chi^2 = 5.24$, $df = 8$; $p = 0.73$). Finally, the sensitivity analysis that utilised a general estimating equation accounting for potential correlations among sites did not result in any important changes in the direction of the effects (adjusted odds for every 10 s increase in closure time: 1.15 with 95% CI 1.10 to 1.23) or conclusions.

DISCUSSION

In this study, we demonstrate that point-of-care testing of platelet reactivity using the PFA-100 is feasible in the environment of the ED. The results of our primary analysis revealed differences in closure times between patients with non-cardiac symptoms versus ACS-positive cohorts, with the most notable, discriminating feature being the higher incidence of prolonged closure times in the group with non-cardiac chest pain. Finally, the outcome of our multivariate analysis is consistent with the concept that the assessment of closure time provides incremental, independent prognostic value beyond that obtained using the standard clinical predictor of TIMI score.

Assessment of platelet reactivity as a diagnostic tool for ACS in emergent settings

It is well-established that heightened platelet activity occurs in the setting of ACS.^{9–11 13 14 32} Indeed, measurement of platelet reactivity has been utilised in an effort to discern the stability of coronary disease,¹⁰ predict the future incidence and outcomes of major adverse cardiovascular events,^{11 33–37} and, although results have been disappointing, guide the dosing of antiplatelet agents with the goal of improving outcomes.^{32 38 39} Our current study differs from these previous reports, in that it focused on the assessment of platelet reactivity as an adjunct strategy to risk stratify patients with potential ACS in emergent conditions. Accordingly, the novelty of our study lies in our expanded analysis of the closure time, and the identification of a more practical and feasible application of these data in the prognosis of ACS.

Our observation of a modest but significant reduction in the median/mean closure times in patients with ACS is consistent with the outcomes of two previous, small ED studies.^{40 41} However, this ~4 s difference is of a limited practical significance given the broad and overlapping distributions of closure times for patients with non-cardiac symptoms and the ACS-positive cohort (figure 2). Rather, we propose *that the clinical utility of*

Table 4 Demographics: UMASS vs Cordoba

	UMASS all (total n=324)	Cordoba all (total n=111)	p Value
Age (years): mean±SD	59±14 (n=324)	56±12 (n=108)	0.036
Male	65% (n=324)	78% (n=111)	0.009
TIMI score: mean±SD	2.3±1.5 (n=313)	2.0±1.4 (n=111)	0.142 (ns)
Aspirin	80% (n=314)	40% (n=104)	<0.0001
Clopidogrel	15% (n=319)	9% (n=111)	0.146 (ns)
Smoker	26% (n=316)	37% (n=111)	0.038
Hypertension	61% (n=316)	51% (n=111)	0.093 (ns)
Hypercholesterolaemia	62% (n=316)	53% (n=111)	0.115 (ns)
Diabetes	28% (n=313)	14% (n=111)	0.005
Family History	44% (n=313)	31% (n=51)	0.014

TIMI, thrombolysis in myocardial infarction.

this test lies in the identification of patients with a prolonged closure time, a threshold that we objectively defined as the 90th centile of the distribution of the study population. In this regard, we found that the prolonged closure time (≥ 138 s) had a high specificity, positive predictive value and likelihood ratio for a diagnosis of non-cardiac chest pain.

Strengths and weaknesses

The results of our pilot study are consistent with the hypothesis that point-of-care testing of platelet reactivity may assist in the timely rule-out of ACS in the ED. Strengths of this approach include the fact that the assessment of closure time is technically straightforward and cost effective, with minimal patient risk (ie, does not involve exposure to radiation or additional invasive testing). In addition, our data suggest that the concept is generalisable. We observed significant differences in demographics (age and gender), the prevalence of specific risk factors (diabetes, smoking) and the use of antiplatelet therapy (aspirin: table 4) between UMASS and Cordoba—findings that are in agreement with the published reports focused on Argentine cohorts,^{30 31 42} and may underlie the robust contribution of study site as a predictor of outcome in our logistic regression model. Nonetheless, our results, obtained from two distinct healthcare systems and populations, consistently revealed a higher proportion of prolonged closure times in patients with non-cardiac symptoms.

There is, however, an important caveat to this strategy. PFA testing will only contribute to the identification of a

subset of patients with non-cardiac symptoms, with the size of the subset and the potential value of the test dependent on the threshold used to define ‘prolonged’ closure times (figure 2 and table 6). For example, the prospective and arbitrary criterion used in our analysis (the 90th centile of closure times for all patients enrolled in the study) discerned an arguably modest 12.4% of patients with a diagnosis of non-cardiac symptoms. However, expediting the discharge of even a small proportion of patients with a non-cardiac diagnosis would limit the costs, potential risks and patient stress associated with unneeded advanced diagnostic testing and possibly invasive procedures.^{1 2} Reducing the threshold (ie, to the 80th centile of the distribution) would




Figure 3 Receiver operating characteristic (ROC) analysis. Comparison of ROC curves obtained by including the closure time, thrombolysis in myocardial infarction (TIMI) score and study site in the regression model versus the TIMI score and site alone showing a significant, incremental increase in area under the curve with the addition of closure time (0.818 vs 0.795; $p=0.009$).

Table 5 Multivariable logistic regression model (outcome modeled: non-cardiac symptoms)

Predictor	Adjusted OR	95% CI
Closure time	1.17	1.06 to 1.29
TIMI risk score	0.48	0.40 to 0.59
Study site	7.21	4.05 to 12.86

(UMASS vs Cordoba).

TIMI, thrombolysis in myocardial infarction.

Table 6 Effect of definition of ‘Prolonged’ closure time on specificity and positive predictive value for a diagnosis of non-cardiac symptoms

Threshold	Specificity, 95% CI (%)	Positive predictive value, 95% CI (%)	Patients with non-cardiac symptoms identified (%)
95th centile (≥ 160 s)	100 (96.6 to 100)	100 (83.9 to 100)	6.4 (21/330)
90th centile (≥ 138 s)	98.1 (93.3 to 99.8)	95.4 (84.2 to 99.4)	12.4 (41/330)
80th centile (≥ 117 s)	88.6 (80.9 to 94.0)	86.2 (77.2 to 92.7)	22.7 (75/330)

increase the size of the subset identified as ACS negative, with an accompanying (and increasingly unacceptable) loss in specificity because of the growing proportion of false positives (ACS-positive patients with prolonged closure times: figure 2 and table 6). In contrast, increasing the threshold (ie, to the 95th centile) would identify a diminishing proportion of patients with non-cardiac symptoms with an increasing specificity (figure 2 and table 6). The appropriate definition of ‘prolonged’ closure time will therefore require refinement based on risk/benefit analysis.

Finally, we emphasise that point-of-care assessment of platelet reactivity and identification of patients with ‘prolonged’ closure times clearly cannot function as a stand-alone test for the rule-out of ACS. Rather, measurement of PFA closure times may serve as an adjunct to the current, standard ED practices. In support of this concept, our multivariate logistic regression model revealed that, irrespective of the TIMI score and study site (and, thus, irrespective of differences in demographics and aspirin use between sites), closure time was an independent predictor of the diagnosis of non-cardiac symptoms.

Summary, limitations and future directions

We report that measurement of the closure time using the PFA-100 provides additional and independent, incremental predictive value in the rule-out of ACS. Limitations of this pilot feasibility study include the enrolment of patients via convenience sampling, and differences in the logistics of the chart review process between the two sites. In addition, neither monitoring of patient outcomes beyond hospital discharge (raising the possibility of potential misclassification of some patients) nor risk/benefit analysis of PFA testing was incorporated into the study design. We emphasise that point-of-care assessment of platelet reactivity cannot serve as a stand-alone test to either discern patients with non-cardiac symptoms versus ACS-positive patients or distinguish between STEMI versus NSTEMI/UA in the emergent setting—limitations that in all likelihood reflect the complex and multifactorial pathophysiology of acute myocardial ischaemia and infarction. Rather, our results suggest that the assessment of closure times may provide benefit by augmenting the standard ED diagnostic practices, a concept that warrants further large-scale multicentre investigation.

Author affiliations

- ¹Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
- ²Cardiovascular Research Institute, Wayne State University School of Medicine Detroit, Michigan, USA
- ³Department of Physiology, Wayne State University School of Medicine Detroit, Michigan, USA
- ⁴Division of Cardiology, Instituto Modelo de Cardiologia Privado SRL, Cordoba, Argentina
- ⁵Department of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
- ⁶Division of Hematology/Oncology, Center for Platelet Research Studies, Boston Children’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
- ⁷Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA

Contributors KP, CED and ADM participated in conception and design of the study; all coauthors participated in analysis and interpretation of the data and final approval of the manuscript; KP, CED, RDW, PW, JASM, CSS and ADM participated in drafting of the manuscript or revising it critically for important intellectual content; all authors have had full access to all data and take responsibility for the integrity of the data and the accuracy of the analysis. KP is the guarantor.

Funding Siemens Inc provided the Emergency Department at the University of Massachusetts Medical School and the Cardiology Department, Instituto Modelo de Cardiologia Privado SRL with PFA-100 devices on a loan basis, as well as partial support for the purchase of test cartridges used in this study. CED was supported in part by a Research Training Grant from the Society for Academic Emergency Medicine (SAEM), Des Plaines, Illinois, USA.

Competing interests None.

Patient consent Obtained.

Ethics approval Institutional Review Boards from the two study sites, University of Massachusetts (UMASS)-Memorial Medical Center, University Campus, Worcester, Massachusetts, USA, and the Cardiology Department, Instituto Modelo de Cardiologia Privado SRL, Cordoba, Argentina.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

1. Amsterdam EA, Kirk JD, Bluemke DA, *et al.* Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. *Circulation* 2010;122:1756–76.
2. Darling CE, Michelson AD, Volturo GA, *et al.* Platelet reactivity and the identification of acute coronary syndromes in the emergency department. *J Thromb Thrombolysis* 2009;28:31–7.

3. Hollander JE, Chang AM, Shofer FS, *et al*. Coronary computed tomographic angiography for rapid discharge of low-risk patients with potential acute coronary syndromes. *Ann Emerg Med* 2009;53:295–304.
4. Litt HI, Gatsonis C, Snyder B, *et al*. CT angiography for safe discharge of patients with possible acute coronary syndromes. *N Engl J Med* 2012;366:1393–403.
5. Hoffmann U, Truong QA, Schoenfeld DA, *et al*. Coronary CT angiography versus standard evaluation in acute chest pain. *N Engl J Med* 2012;367:299–308.
6. Hoffmann U, Truong QA, Fleg JL, *et al*. Design of the rule out myocardial ischemia/infarction using computer assisted tomography: a multicenter randomized comparative effectiveness trial of cardiac computed tomography versus alternative triage strategies in patients with acute chest pain in the emergency department. *Am Heart J* 2012;163:330–8, 8 e1.
7. Singer AJ, Domingo A, Thode HC Jr., *et al*. Utilization of coronary computed tomography angiography for exclusion of coronary artery disease in ED patients with low- to-intermediate-risk chest pain: a 1-year experience. *Am J Emerg Med* 2012;30:1706–11.
8. Hulten E, Pickett C, Bittencourt MS, *et al*. Outcomes after coronary computed tomography angiography in the emergency department: a systematic review and meta-analysis of randomized, controlled trials. *J Am Coll Cardiol* 2013;61:880–92.
9. Ault KA, Cannon CP, Mitchell J, *et al*. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in myocardial infarction. *J Am Coll Cardiol* 1999;33:634–9.
10. Linden MD, Furman MI, Frelinger AL III., *et al*. Indices of platelet activation and the stability of coronary artery disease. *J Thromb Haemost* 2007;5:761–5.
11. Gurbel PA, Becker RC, Mann KG, *et al*. Platelet function monitoring in patients with coronary artery disease. *J Am Coll Cardiol* 2007;50:1822–34.
12. Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. *J Cardiovasc Pharmacol Ther* 2009;14:157–69.
13. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. *Nat Rev Drug Discov* 2010;9:154–69.
14. Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes. *J Am Coll Cardiol* 2013;61:1–11.
15. Hollander JE, Muttreja MR, Dalesandro MR, *et al*. Risk stratification of emergency department patients with acute coronary syndromes using P-selectin. *J Am Coll Cardiol* 1999;34:95–105.
16. Furman MI, Benoit SE, Barnard MR, *et al*. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. *J Am Coll Cardiol* 1998;31:352–8.
17. Michelson AD, Barnard MR, Krueger LA, *et al*. Evaluation of platelet function by flow cytometry. *Methods* 2000;21:259–70.
18. Michelson AD. Methods for the measurement of platelet function. *Am J Cardiol* 2009;103:20A–6A.
19. Crescente M, Mezzasoma AM, Del Pinto M, *et al*. Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin. *Platelets* 2011;22:179–87.
20. Linnemann B, Schwonberg J, Rechner AR, *et al*. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. *Ann Hematol* 2010;89:597–605.
21. Poulsen TS, Jorgensen B, Korsholm L, *et al*. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. *Thromb Res* 2007;119:555–62.
22. Poulsen TS, Mickley H, Korsholm L, *et al*. Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. *Thromb Res* 2007;120:161–72.
23. Antman EM, Cohen M, Bernink PJ, *et al*. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. *JAMA* 2000;284:835–42.
24. O'Gara PT, Kushner FG, Ascheim DD, *et al*. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;127:529–55.
25. Thygesen K, Alpert JS, Jaffe AS, *et al*. Third universal definition of myocardial infarction. *Circulation* 2012;126:2020–35.
26. Anderson JL, Adams CD, Antman EM, *et al*. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;127:e663–828.
27. Hilden J, Gerds TA. A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index. *Stat Med* 2013;Epub 2 April 2013.
28. Kerr KF, Wang Z, Janes H, *et al*. Net reclassification indices for evaluating risk prediction instruments: a critical review. *Epidemiology* 2014;25:114–21.
29. Kelly AM. What is the incidence of major adverse cardiac events in emergency department chest pain patients with a normal ECG, thrombolysis in myocardial infarction score of zero and initial troponin <=99th centile: an observational study? *Emerg Med J* 2013;30:15–18.
30. Bernardi V, Szarfer J, Summay G, *et al*. Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent (RACS) trial). *Am J Cardiol* 2007;99:349–52.
31. Bernztein RG, Drake I. Use of aspirin in the public primary care level: experience of the Remediar Program, Argentina. *Rev Argent Cardiol* 2010;78:330–8.
32. Collet JP, Cuisset T, Range G, *et al*. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. *N Engl J Med* 2012;367:2100–9.
33. Christie DJ, Kottke-Marchant K, Gorman RT. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. *Platelets* 2008;19:104–10.
34. Atiemo AD, Ng'Alla LS, Vaidya D, *et al*. Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain. *J Thromb Thrombolysis* 2008;25:173–8.
35. Bevilacqua S, Alkodami AA, Volpi E, *et al*. Risk stratification after coronary artery bypass surgery by a point-of-care test of platelet function. *Ann Thorac Surg* 2009;87:496–502.
36. Bonello L, Tantry US, Marcucci R, *et al*. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. *J Am Coll Cardiol* 2010;56:919–33.
37. Breet NJ, van Werkum JW, Bouman HJ, *et al*. The relationship between platelet reactivity and infarct-related artery patency in patients presenting with a ST-elevation myocardial infarction. *Thromb Haemost* 2011;106:331–6.
38. Price MJ, Berger PB, Teirstein PS, *et al*. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA* 2011;305:1097–105.
39. Ang L, Thani KB, Ilapakurti M, *et al*. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. *J Am Coll Cardiol* 2013;61:23–34.
40. Frossard M, Fuchs I, Leitner JM, *et al*. Platelet function predicts myocardial damage in patients with acute myocardial infarction. *Circulation* 2004;110:1392–7.
41. Harrison P, Mackie I, Mathur A, *et al*. Platelet hyper-function in acute coronary syndromes. *Blood Coagul Fibrinolysis* 2005;16:557–62.
42. Moran A, Degennaro V, Ferrante D, *et al*. Coronary heart disease and stroke attributable to major risk factors is similar in Argentina and the United States: the Coronary Heart Disease Policy Model. *Int J Cardiol* 2011;150:332–7.